Stockchase Opinions

Neil Murdock Amgen Inc. AMGN-Q BUY ON WEAKNESS Jan 13, 2003

Very successful biotech. Big growth. May be a little high.
$51.520

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK

Trades at a healthy 15x earnings and 66% gross margin (56% in the sector). It pays a 3% dividend. They just bought Horizon Therapeutics which adds growth. Their early-stage obesity drug shows great promise in a $100 billion potential market.

(Analysts’ price target is $319.54)
BUY
vs. NVO and LLY

He prefers Amgen, because their weight-loss drug is under trial and not priced into the stock yet. And it trades at a lower PE than these peers.

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Apr 11/24, Up 22%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with AMGN is progressing well.  To remain disciplined, we recommend trailing up the stop (from $260) to $294 at this time.  

BUY

They just bought Horizon Therapeutics, a growth engine, and have a weight-loss drug in phase 2 trials that is promising facing a huge market. They trade at a decent PE and enjoy good growth from their core drugs.

BUY

Today's downgraded doesn't bother him. These calls go back and forth often. Their weight-loss drug could add $10 billion revenues. A good time to own this.

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Apr 11/24, Up 8.6%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with AMGN has triggered its stop at $294.  To remain disciplined, we recommend covering the position at this time. 

DON'T BUY

He still believes in their key drug, Repatha. His concern lies with their weight-loss drug and their disappointing results.

BUY

A dividend play for 2025 at 3.65%. Not sexy, but consistently generates earnings, free cash flow, and each year grows its dividend. Offers growth wealth generation over time.

BUY

Diversity is good in the bio pharma space. It is a fully diversified large cap and he would have it as a core holding.

BUY

Phase 2 drug in the GLP-1 space -- not as mature as LLY's drug, but you don't pay as much for this company either. Trades ~14x earnings, compared to 50x for LLY. And that's more his style of investing.